Daily Pivots: (S1) 156.41; (P) 156.69; (R1) 156.97; More… Intraday bias in USD/JPY stays neutral and outlook is unchanged. On the downside, break of 155.01 will resume the fall from 160.71 to 152.25 support next. Read more…
Daily Pivots: (S1) 1.1740; (P) 1.1764; (R1) 1.1806; More…. Intraday bias in EUR/USD stays neutral as sideway trading continues. Further rise is expected with 1.1642 support intact. On the upside, firm break of 1.1848 will Read more…
Warren Buffett has spent 60 years watching financial markets through every kind of cycle, including bull runs, crashes, manias, and recoveries. He says only five of those years were truly “juicy” with opportunity. He used Read more…
Daily Pivots: (S1) 1.3568; (P) 1.3602; (R1) 1.3659; More… Range trading continues in GBP/USD and intraday bias stays neutral for the moment. With 1.3453 support intact, further rise is expected. On the upside, break of Read more…
Markets moved into a more cautious tone today as the deadlock in US-Iran peace negotiations continued to drag on, while renewed volatility in UK government bonds added another layer of political and fiscal uncertainty. However, Read more…
The median home price in the United States is now roughly $436,000. Mortgage rates hover around 6.2%, and first-time buyers have dropped to their lowest share on record at just 21% of all purchasers, USA Read more…
Peter Suhm shares a simple Todoist setup that separates tasks due on a specific day from tasks that just need to happen this week. The heart of the system is a single custom filter that Read more…
Goldman Sachs doesn’t think the Federal Reserve will give the markets what they want. According to TheFly, the bank expects the next two Fed interest rate cuts to come in December 2026 and March 2027, Read more…
Silver bulls are quietly winning an important battle — even if prices are not exploding higher yet. Under normal market conditions, Silver should have suffered a much deeper pullback by now. Dollar has rebounded broadly Read more…
Dr. Andrew Snyder (Monash University) joins the show to discuss the current biotech landscape: rising M&A and IPO activity, where clinical-stage assets are attracting buyers, and which therapeutic areas are gaining momentum (oncology, rare disease, Read more…